Literature DB >> 12717354

Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study.

Dominique Elias1, Philippe Lasser, Michel Ducreux, Pierre Duvillard, Jean-Francois Ouellet, Clarice Dromain, Martin Schlumberger, Marc Pocard, Valérie Boige, Catherine Miquel, Eric Baudin.   

Abstract

BACKGROUND: The timing and benefits of hepatectomy remain controversial for metastatic well-differentiated endocrine neoplasms, which are generally considered slow growth tumors. However, surveillance alone yields only a 22% 5-year survival when metastases occur. The aim of this study was to determine the results of hepatic and extra hepatic resections and to clarify the indications of surgery.
METHODS: To define the role of hepatic resection, a database regrouping all patients (n = 47) who underwent hepatectomy with curative intent (R0 status) for well-differentiated endocrine neoplasms in the Gustave-Roussy Institute was constructed in 1984. New prognostic factors such as tumor growth and liver tumor mitotic index were studied. Median follow-up was 62 months.
RESULTS: Hepatectomy was associated with extrahepatic tumor resection in 77% of the patients (primary tumor in 51%, lymph nodes in 21%, peritoneal carcinomatosis in 25%, and other in 6%). Resection was curative (R0) only in 53% of the patients, despite removing at least 97% of the tumor in each patient. Mortality was 5%, and morbidity was 45%. Median survival was 91 months, 5-year and 10-year overall survival rates were 71% and 35%, respectively. Liver recurrence rate was 75% at 10 years. No prognostic factor was correlated with overall survival in this population in which at least 97% of the tumor load was resected. The completeness of surgery, the presence of bilateral liver metastases, the number of liver metastases (>10) and a primary tumor from pancreatic origin were all significantly correlated with the disease-free survival. Preoperative tumor growth rate, mitotic index, and Ki67 expression were not predictive of prognosis. No significant prognostic factors could be found by the comparison of the patients who did and did not recur during the 3 years after hepatectomy.
CONCLUSION: Hepatectomy for liver metastases from well-differentiated endocrine neoplasms is indicated when all visible intra- and extra hepatic lesions can be resected safely. The number, size, and localization of the tumor sites are less important than performing a complete (or near-complete) resection.

Entities:  

Mesh:

Year:  2003        PMID: 12717354     DOI: 10.1067/msy.2003.114

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  57 in total

1.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  Reported outcome factors for hepatic metastasectomy.

Authors:  N Joseph Espat
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

3.  Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables.

Authors:  Linda S Sher; David M Levi; Julie S Wecsler; Mary Lo; Lydia M Petrovic; Susan Groshen; Lingyun Ji; Teresa Diago Uso; A Joseph Tector; Ann S Hamilton; J Wallis Marsh; Myron E Schwartz
Journal:  J Surg Oncol       Date:  2015-07-14       Impact factor: 3.454

4.  Prognostic significance of metastatic lymph node number, ratio and station in gastric neuroendocrine carcinoma.

Authors:  Xiaolong Tang; Yingtai Chen; Lanwei Guo; Jianwei Zhang; Chengfeng Wang
Journal:  J Gastrointest Surg       Date:  2014-11-14       Impact factor: 3.452

Review 5.  When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations.

Authors:  Mickaël Lesurtel; David M Nagorney; Vincenzo Mazzaferro; Robert T Jensen; Graeme J Poston
Journal:  HPB (Oxford)       Date:  2014-03-17       Impact factor: 3.647

6.  CT differentiation of poorly-differentiated gastric neuroendocrine tumours from well-differentiated neuroendocrine tumours and gastric adenocarcinomas.

Authors:  Seong Ho Kim; Se Hyung Kim; Min-A Kim; Cheong-il Shin; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

Review 7.  Surgical management of pancreatic neuroendocrine tumors.

Authors:  Wataru Kimura; Koji Tezuka; Ichiro Hirai
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

8.  Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies.

Authors:  Stefano Bacchetti; Enrico Maria Pasqual; Serena Bertozzi; Ambrogio P Londero; Andrea Risaliti
Journal:  Gland Surg       Date:  2014-11

Review 9.  Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.

Authors:  Skye C Mayo; Joseph M Herman; David Cosgrove; Nik Bhagat; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-10-11       Impact factor: 6.113

10.  Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment.

Authors:  Liliana Chiorean; Adrian Bartos; Doris Pelau; Dana Iancu; Tudor Ciuleanu; Rares Buiga; Irinel Oancea; Angelica Mangrau; Cornel Iancu; Radu Badea
Journal:  J Med Ultrason (2001)       Date:  2014-10-25       Impact factor: 1.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.